Novo Nordisk AS
(OCSE:NOVO B)
kr
775.8
18.5 (2.44%)
Market Cap: 3.45 Til
Enterprise Value: 3.43 Til
PE Ratio: 36.59
PB Ratio: 28.65
GF Score: 97/100 
Q3 2024 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 07, 2024- Q3 2024 Novo Nordisk A/S Earnings Call TranscriptNov 06, 2024kr749.5 (+0.55%)Earnings
- Q2 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 08, 2024kr864 (+4.30%)Earnings
- Q2 2024 Novo Nordisk A/S Earnings Call TranscriptAug 07, 2024kr828.4 (-6.71%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 03, 2024kr850.6 (-2.58%)Earnings
- Q1 2024 Novo Nordisk A/S Earnings Call TranscriptMay 02, 2024kr873.1 (-2.74%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2024
- Novo Nordisk A/S Capital Markets Day TranscriptMar 07, 2024
- Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 01, 2024kr786.4 (+1.50%)Earnings
- Q4 2023 Novo Nordisk A/S Earnings Call TranscriptJan 31, 2024kr774.8 (+3.56%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Novo Nordisk A/S at American Heart Association Conference TranscriptNov 11, 2023
- Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2023kr683.9 (-3.61%)Earnings
- Q3 2023 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2023kr709.5 (+3.17%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 11, 2023kr620.6 (-0.54%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call TranscriptAug 10, 2023kr624 (-1.22%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 26, 2023
- Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 09, 2023kr570.9 (-0.37%)Earnings
- Q1 2023 Novo Nordisk A/S Earnings Call TranscriptMay 04, 2023kr547 (-2.60%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 23, 2023
- Q4 2022 Novo Nordisk A/S Earnings Call TranscriptFeb 01, 2023kr471.2 (-0.06%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2022kr428.3 (-0.46%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2022kr430.3 (+7.44%)Earnings
- Novo Nordisk A/S at JPMorgan CEO Call Series TranscriptSep 14, 2022
- Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 05, 2022kr378 (-2.96%)Earnings
- Q2 2022 Novo Nordisk A/S Earnings Call TranscriptAug 03, 2022kr385.6 (-9.40%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA TranscriptJun 06, 2022
- Q1 2022 Novo Nordisk A/S Earnings Presentation - London TranscriptMay 05, 2022
- Q1 2022 Novo Nordisk A/S Earnings Call TranscriptApr 29, 2022kr406.15 (+5.38%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 24, 2022
- Novo Nordisk A/S Capital Markets Day TranscriptMar 03, 2022
- Q4 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 04, 2022kr323.25 (-5.07%)Earnings
- Q4 2021 Novo Nordisk A/S Earnings Call TranscriptFeb 02, 2022kr350.25 (+4.37%)Earnings
- Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call TranscriptDec 20, 2021
- Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 04, 2021
- Q3 2021 Novo Nordisk A/S Earnings Call TranscriptNov 03, 2021kr365.8 (+2.46%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 06, 2021kr313.45 (-2.46%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call TranscriptAug 04, 2021kr305.5 (+4.78%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 28, 2021
- Novo Nordisk A/S Approval of Wegovyâ„¢ in the United States Investor Call TranscriptJun 07, 2021
- Novo Nordisk A/S to Discuss International Operations Call TranscriptMay 21, 2021
- Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 06, 2021kr227.8 (-0.79%)Earnings
- Q1 2021 Novo Nordisk A/S Earnings Call TranscriptMay 05, 2021kr229.63 (+0.35%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 25, 2021
- Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 05, 2021kr220.2 (-0.96%)Earnings
- Q4 2020 Novo Nordisk A/S Earnings Call TranscriptFeb 03, 2021kr225 (+2.74%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call TranscriptDec 16, 2020
- Novo Nordisk A/S ESG Conference Call TranscriptNov 30, 2020
- Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 02, 2020kr208.35 (+1.50%)Earnings
- Q3 2020 Novo Nordisk A/S Earnings Call TranscriptOct 30, 2020kr205.28 (-3.41%)Earnings
- Novo Nordisk A/S to Discuss Updated 2020 Outlook Call TranscriptOct 09, 2020
- Q2 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 07, 2020kr203.38 (+1.59%)Earnings
- Q2 2020 Novo Nordisk A/S Earnings Call TranscriptAug 06, 2020kr200.2 (-1.81%)Earnings
- Novo Nordisk A/S Virtual R&D Investor Call (Q&A) TranscriptJun 19, 2020
- Novo Nordisk A/S Virtual R&D Investor Presentation TranscriptJun 19, 2020
- Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2020
- Q1 2020 Novo Nordisk A/S Earnings Call TranscriptMay 06, 2020kr216.35 (+0.60%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Q4 2019 Novo Nordisk A/S Earnings Presentation TranscriptFeb 06, 2020
- Q4 2019 Novo Nordisk A/S Earnings Call TranscriptFeb 05, 2020kr217.5 (+4.58%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Novo Nordisk A/S Capital Markets Day TranscriptNov 20, 2019
- Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call TranscriptNov 18, 2019
- Q3 2019 Novo Nordisk A/S Earnings Presentation TranscriptNov 04, 2019
- Q3 2019 Novo Nordisk A/S Earnings Call TranscriptNov 01, 2019kr189.45 (+3.57%)Earnings
- Novo Nordisk A/S to Discuss Rybelsus® US Approval Call TranscriptSep 23, 2019
- Q2 2019 Novo Nordisk A/S Earnings Presentation TranscriptAug 12, 2019
- Q2 2019 Novo Nordisk A/S Earnings Call TranscriptAug 09, 2019kr167 (-0.24%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA 2019 TranscriptJun 10, 2019
- Q1 2019 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2019
- Q1 2019 Novo Nordisk A/S Earnings Call TranscriptMay 03, 2019kr158.68 (-2.97%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2019
Novo Nordisk A/S ESG Conference Call Transcript
Nov 30, 2020 / 03:00PM GMT
Release Date Price:
kr209.85
(+0.11%)
Operator
Hello, and welcome to the Novo Nordisk A/S conference call. (Operator Instructions) Today, I'm pleased to present Lars Fruergaard Jørgensen, CEO. Please go ahead with your meeting.
Lars Fruergaard JÃ;rgensen;S;President
Novo Nordisk A;CEO & Member of Management Board
¸ - /- -
Thank you very much, and welcome to this conference call regarding our approach to sustainability.
With me today, I have Camilla Sylvest, Executive Vice President and Head of Commercial Strategy and Corporate Affairs. I also have Henrik Wulff, Executive Vice President of Product Supply, Quality and IT. I also have Monique Carter, Executive Vice President of People and Organization. And finally, I have Karsten Munk Knudsen, Executive Vice President and Chief Financial Officer.
Please turn to Slide 2. We will to today be making forward-looking statements, and I have to remind you that such forward-looking statements would include risks and uncertainties. So please look at Slide 2 and also make reference to our
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers